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Abstract
Background: the study was designed to determine how tumour hormone receptor status affects the subsequent
pattern over time (dynamics) of breast cancer recurrence and death following conservative primary breast cancer
resection.
Methods: Time span from primary resection until both first recurrence and death were considered among 2825
patients undergoing conservative surgery with or without breast radiotherapy. The hazard rates for ipsilateral breast
tumour recurrence (IBTR), distant metastasis (DM) and mortality throughout 10 years of follow-up were assessed.
Results: DM dynamics displays the same bimodal pattern (first early peak at about 24 months, second late peak at
the sixth-seventh year) for both estrogen receptor (ER) positive (P) and negative (N) tumours and for all local
treatments and metastatic sites. The hazard rates for IBTR maintain the bimodal pattern for ERP and ERN tumours;
however, each IBTR recurrence peak for ERP tumours is delayed in comparison to the corresponding timing of
recurrence peaks for ERN tumours. Mortality dynamics is markedly different for ERP and ERN tumours with more
early deaths among patients with ERN than among patients with ERP primary tumours.
Conclusion: DM dynamics is not influenced by the extent of conservative primary tumour resection and is similar
for both ER phenotypes across different metastatic sites, suggesting similar mechanisms for tumour development
at distant sites despite apparently different microenvironments. The IBTR risk peak delay observed in ERP tumours
is an exception to the common recurrence risk rhythm. This suggests that the microenvironment within the
residual breast tissue may enforce more stringent constraints upon ERP breast tumour cell growth than other
tissues, prolonging the latency of IBTR. This local environment is, however, apparently less constraining to ERN cells,
as IBTR dynamics is similar to the corresponding recurrence dynamics among other distant tissues.
Background
Our previous work [1] provides evidence that, when mas-
tectomy and axillary dissection are performed as initial
treatment for breast cancer, there is a very predictable
nonlinear temporal pattern to the subsequent risk for
recurrence and death. There are two peaks in recurrence
risk, regardless of the hormone receptor status of the
resected primary tumour. The first occurs very early, at
the second-third year, while the second peak occurs years
later. Even though the risk peaks occur at about the same
time following primary cancer resection, regardless of
tumour hormone receptor status, the overall risk level of
early recurrence is much higher for patients bearing
Estrogen Receptor (ER) negative (N) tumours than for
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recurrence peak is, oppositely, higher for ERP and lower
for ERN tumours. Thus the two hazard curves intersect
at the third year, as observed by others [2,3]. Contrary to
recurrence dynamics, however, the hazard rate pattern
for mortality displays simpler dynamics, as death for ERP
tumours is delayed compared to ERN tumours.
The distinct and predictable recurrence and subse-
quent death risk patterns indicate a likely synchronizing
effect of the surgical resection upon subsequent meta-
static cancer development, apparently similar in all
seeded distant organs [4]. This synchronizing effect,
probably accelerates early recurrence and subsequent
death, occurs for both types of breast cancer but much
more lethal in the early post surgery span for ERN
tumours. The observed differences in the mortality risk
pattern between ERP and ERN tumours may in part be
explained by the higher frequency of visceral metastasis
for ERN tumours [5,6], and also by their lack of response
to hormone therapy [7,8]. Additionally, the resection-
associated recurrence following primary tumour resec-
tion displays an apparently similar time-course for every
ER class, suggesting caution in the interpretation of the
clinical meaning of the two main subtypes of breast can-
cer identified by epidemiological features linked to ER
expression [9] and gene expression profiling (luminal A
and basal-like, phenotypically referred as ERP and ERN,
respectively) [10] as well as the distinct gene expression
patterns associated with ER status [11].
Our earlier findings [1] were described in an era of lar-
ger primary resections. Since breast cancer surgery has
become progressively more conservative, we now report
whether the same bimodal breast cancer recurrence pat-
terns follow smaller operations. The availability of ten
year follow up for nearly three thousand such patients
treated at the Milan National Cancer Institute allows us
to determine whether the dynamics of recurrence follow-
ing a lesser resection has the same shape over time as
mastectomy; whether it is affected by the difference
between tumourectomy and the larger conservative
resection of quadrantectomy; whether the dynamics of
distant recurrence differ by ER status of the primary
tumour in this surgical setting and whether the dynamics
of post resection differ according to the organ site of that
distant spread. Finally, because of the large number of
patients studied we are also able to determine whether
these recurrence dynamics differed when the recurrence
occurred within the ipsilateral previously resected breast
as compared to other distant sites.
Methods
The data derived from patients undergoing conservative
surgery within a series of randomized clinical trials carried
out at the Milan National Cancer Institute, investigating
the role of different approaches for the primary tumour
treatment, were scrutinized. In the Milan Institute, since
the preliminary results of the first trial on the conservative
treatment of early breast cancer [12] were reported to be
as good as or better than more aggressive resections, this
treatment became routine practice. This has allowed for
data from cases comparably treated outside randomized
clinical trials (out-trial patients) to be systematically
recorded as for in-trial patients and this database was
included in the analysis as well.
In one trial, patients with invasive breast carcinoma 2,5
cm or less were randomized to either quadrantectomy,
complete axillary dissection and radiotherapy (QuaRT)
(360 women) or tumourectomy plus axillary dissection
and radiotherapy (TaRT) (345 women). Quadrantectomy
involved radial breast resection with excision of 2-3 cm
of normal tissue around the tumour plus the removal of
a sufficiently large portion of overlying skin and underly-
ing fascia whilst lumpectomy removed only the tumour
mass with a margin of normal tissue of 1 cm. In a suc-
ceeding trial eligibility criteria were identical and patients
were randomized to QuaRT (294 women) or quadran-
tectomy plus axillary dissection without radiotherapy
(Quad) (273 women). The full series of out-trial patients,
who received QuaRT for unilateral primary breast cancer,
amounts to 1652 patients. All analyzed trials were per-
formed with the approval of the ethics committee of the
Milan National Cancer Institute and patients were
enrolled following informed consent.
With the exception of patients allocated to the Quad
arm, who did not receive radiotherapy, all patients
received a radiation dose of 60 Gy to the ipsilateral
breast. All axillary node positive (N+) patients were
offered systemic adjuvant treatment [Cyclophosphamide
plus Methotrexate plus Fluorouracil (CMF) or CMF
plus Doxorubicin (Dx)], while no further post-surgical
systemic treatment was recommended to axillary node
negative (N-) patients. Adjuvant hormone therapy was
not utilized within the randomized clinical trials and
infrequently employed for out-trial patients, as it was
not considered mandatory at that time. Details of the
two trials and of the out-trial series have been reported
elsewhere [13-15].
All baseline data, treatment features and relevant clini-
cal events were collected in standard format and stored
in a clinical database, from which, after excluding 99
patients for whom the pathological T classification
could not be determined, data of the 2552 patients
undergoing conservative surgery plus RT and the 273
patients receiving quadrantectomy without RT were
extracted for the present analysis. ER status was mea-
sured by the dextran-coated charcoal method and
tumours with ER values >10 fmol/mg protein were con-
sidered ERP.
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metastasis (DM) as first events and death from any cause
were considered in the analysis. IBTR was defined as any
new breast cancer focus appearing in the operated breast.
DM was defined as any breast cancer manifestation(s) in
areas other than that of IBTR with the exception of the
contralateral breast. All diagnosed primary tumours,
including contralateral breast cancers, were considered as
competing events. In order to avoid the usual uncertain-
ties related to the cause of death, deaths from any cause
were studied instead of breast cancer related deaths only.
Flexible piecewise exponential regression models for
the hazard function were performed by subdividing
observed time data in three months intervals [1]. For a
smoothed estimate of the hazard function, Natural Cubic
Spline with fixed boundary knots, at which the natural
(linear) boundary conditions are imposed, were used for
their better conditioning on the tail in avoiding fluctua-
tions due to few and strewn events on late follow-up.
These enforce the constraint that the function is linear
beyond boundary knots. Boundary knots were imposed
in 1.5 - first observed time as default - and in 106.5 - as
no more than a dozen events are left on the right side.
Models included interaction terms, allowing for the esti-
mate of the possible change of the hazard according to
ER status. The evidence of different behaviours was infor-
mally assessed by model selection according to the
Akaike Information Criterion (AIC). When studying
hazard rates according to ER status following an explora-
tory perspective, models with a different shape for the
hazard according to ER status were adopted. Since the
response of the used regression model is the logarithm of
the cause-specific hazard, the 95% confidence interval is
based on log-transformation and this fact prevent them
to be symmetric. The width of confidence intervals are
m a i n l yd e t e r m i n e db yt h es a m p l es i z ea n dt h es i z eo ft h e
uncensored subject group.
Crude cumulative incidence for IBTR and DM was
non-parametrically estimated to account for the pre-
sence of competing events.
Results
Patient Characteristics
The main characteristics of patients are reported in Table
1. Median age was 49 years (range 21 - 79 years) and 57.1%
of patients were premenopausal. Median tumour size was
1.5 cm (range 0.2 - 4.3 cm) and 38.2% of cases had axillary
lymph node invasion. Adjuvant systemic chemotherapy
(CMF ± Dx) was administered to 73.2% of N+ patients,
and 153 patients (14.2%) received Tamoxifen only.
The median follow-up time is 121 months. The num-
ber of recurring patients and the number of deceased
patients at 5 and 10 years of follow-up are reported in
Table 2. Hormone receptor status was obtained for
81.2% of tumours (Table 1). Patients with ERN tumours
were more likely premenopausal and had tumours
slightly larger than patients with ERP tumours, while
the axillary nodal status was similar in both ER levels.
Overall Outcomes
At 10 years of follow-up, ERP and ERN patients showed
the same crude cumulative incidence of total recurrence
(36%) as well as similar frequency of IBTR (12.6% and
11.1%, respectively) or DM (23.9% and 24.6%, respec-
tively); suggesting that ER status per se did not influence
t h ec u m u l a t i v er a t eo fr e c u r r e n c e .A l s o ,t h el a t eo u t -
come for ERP and ERN tumours was similar with global
survival of 76.6% and 72.7% respectively.
Distant Recurrence Dynamics
The patterns of the hazard rate for DM for patients
undergoing different local treatments are reported in
Figure 1. The bimodal recurrence dynamics (early peak
at about 24 months, late peak at the sixth-seventh year)
is manifest for all treatment groups.
When the DM dynamics was related to the ER status,
patients with ERP tumours receiving different local treat-
ments displayed hazard rates for DM with remarkably
similar patterns (Figure 2). Regrettably, similar compari-
son could not be performed for patients with ERN
tumours, because of inadequate number of such patients
Table 1 Main patient characteristics
All ERP ERN
Total number 2825 1811 482
Age
≤ 45 972 551 184
46 – 55 992 643 179
56 – 65 631 453 89
>65 230 164 30
Menopausal status
Pre 1613 972 291
Post 1201 837 190
Unknown 11 3 1
Tumor size
≤2 cm 2428 1558 383
>2 cm 397 253 99
Nodal status
N- 1745 1097 299
N + (1-3) 771 504 122
N + (>3) 309 210 61
Adjuvant therapy (for N + patients)
none 68 39 12
CMF ± Dx 790 513 145
Tamoxifen 153 120 17
Other 10 5
Unknown 59 37 9
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Page 3 of 9receiving TaRT or Quad. Therefore, the recurrence risk
patterns by ER status were estimated and compared
within the group of patients receiving conservative sur-
gery (quadrantectomy or tumourectomy) plus RT. Once
again a bimodal structure emerged for both ER levels
with a first dominant early peak at the end of the second
year after primary tumour removal (Figure 3). During the
third year the two curves intersect and the DM risk for
ERN tumours drops under the corresponding value of
ERP tumours after the fifth year.
Finally, the DM dynamics in different metastasis sites
(soft tissue, bone, viscera) was analyzed in the subset of
patients for whom the treatment protocol required
recording this information. Such patients received con-
servative surgery plus RT. The model allowing for the
cause specific hazard to have a different behaviour
according to ER group, but only a different scale level
according to the different metastatic sites, was actually
selected in agreement with previous results [4]. For ERP
tumours the hazard rate curves display similar bimodal
pattern for all sites, albeit with different risk levels
(Figure 4A). Comparable results emerge for DM to vis-
cera and bone for patients with ERN tumours, while the
limited number of events prevented to reliably analyze
DM to soft tissue for these patients (Figure 4B).
Local Recurrence Dynamics
IBTR dynamics was analyzed in patients undergoing
conservative surgery plus RT. The general bimodal pat-
tern emerges for both ER levels (Figure 5). However, the
dynamics of local recurrence are quite different depend-
ing upon whether the resected tumor does or does not
bear sex hormone receptors. Hormone receptor negative
cancers recur in the resected irradiated breast with a
sharp high early peak and with a clear second peak four
years later. Hormone receptor bearing primary tumors
r e c u rw i t hab r o a d e ra n dl o w e rf i r s tp e a ka n daw i d e
later peak. Both the early and the late peak of ERP
tumours are delayed of about 1,5 and 2,5 years, respec-
tively, in comparison with the corresponding peaks of
ERN tumours. The slight overlapping of the confidence
intervals does not conflict with the major hazard rate
patterns, although some major care is needed for later
times when events are observed to be quite spread.
Mortality dynamics
In spite of the fact that the cumulative mortality is quite
similar for both ER categories, the mortality chronology is
definitely different for ERP and ERN tumours (Figure 6).
Table 2 Number of events at 5 and 10 years of follow-up
5 years 10 years
Cons. Plus RT – 2552 patients
IBTR 130 217
DM 396 521
Deaths 478 590
Quad – 273 patients
IBTR 41 62
DM 22 37
Deaths 47 66
Figure 1 Hazard rate estimates for distant metastasis in 2204
patients undergoing QuaRT, 348 patients receiving TaRT and
273 patients given Quad. The ubiquitous bimodal distant
recurrence dynamics described previously following mastectomy are
present when much smaller operations are employed. Radiation of
the chest wall clearly does not eliminate or even delay the first early
recurrence peak. Vertical lines represent point-wise confidence
interval for the model estimated hazards, according to standard
asymptotic theory.
Figure 2 Hazard rate estimates for distant metastasis in
patients with ERP tumours undergoing QuaRT (1354 patients),
TaRT (261 patients) and Quad (196 patients). There is virtual
identity of distant recurrence dynamics for each conservative local
treatment modality among ERP tumours. Vertical lines represent
point-wise confidence interval for the model estimated hazards,
according to standard asymptotic theory.
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a slow increase in level reaching a plateau at the fifth-sixth
year, while for patients with ERN tumours the rise is
much steeper with a spike at the third year. ERN tumours
show a further mortality peak at about 60 months while
for ERP tumours a second mortality peak is blurry indis-
tinct and hardly detectable at the same time. The hazard
rate curve of patients with ERN tumours crosses the cor-
responding curve of patients with ERP tumours between
the sixth and the seventh year and persists at a lower level
afterwards.
Discussion
Distant Recurrence Dynamics
This explorative investigation of a large and mature data-
base provides evidence that the bimodal DM dynamics,
previously observed in patients undergoing mastectomy
for early breast cancer, is also present in patients under-
going more conservative resections with or without RT.
The peak recurrence timing for these patients (Figure 1)
is comparable to that observed in patients undergoing
mastectomy [1,16]. These data further support our
hypothesis that surgical synchronization of distant
Figure 3 Hazard rate estimates for distant metastasis in 1615
ERP tumours 427 ERN tumours from patients undergoing
conservative surgery (quadrantectomy or tumourectomy) plus
RT. These data show that the recurrence peak timing after
conservative resection is maintained regardless of tumour hormonal
receptor status. Patients with ERN tumours do worse during early
years and better later. Vertical lines represent point-wise confidence
interval for the model estimated hazards, according to standard
asymptotic theory.
Figure 4 Hazard rate estimates for distant metastasis by metastatic site in 1528 ERP tumours (A) and in 391 ERN tumours (B) from
patients undergoing conservative surgery (quadrantectomy or tumourectomy) plus RT. The similarity of recurrence dynamics provides
evidence that recurrence timing is generated by factors influencing the metastatic development, regardless of the seeded organ. Vertical lines
represent point-wise confidence interval for the model estimated hazards, according to standard asymptotic theory.
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supports the concept that local treatment modalities do
not appreciably modify the growth traits of the DM pro-
cess. In Figure 1, the early risk level for patients not given
RT is considerably lower than the corresponding risk of
patients receiving RT. This counterintuitive finding may
be reasonably related to the fact that the omission of RT
over the resected breast area results in very high rate of
IBTR as first event that may in turn partially obscure the
competing DM rate. In spite of this, the DM risk pattern
for these patients emerges unmistakably, confirming that
RT to the chest wall does not eliminate or even delay the
first early recurrence peak. In a similar way one can
explain the finding that patients receiving TaRT show a
moderately lower first peak height than patients given
QuaRT, who experienced lower IBTR rates, as it was
already noted [13].
The similarity between the hazard rate patterns for all
patients and for patients with ERP tumours (Figures 1
a n d2 ) ,i n d i r e c t l ys u g g e s t st h a tE Rs t a t u sd o e sn o t
appreciably change the DM dynamics for any local treat-
ment modality in this subset of patients most of whom
did not receive hormone therapy. This notion is further
supported by the analysis of the DM risk pattern by ER
status for patients receiving postoperative RT (Figure 3).
Both ERP and ERN tumours display similar bimodal
dynamics, regardless of the small differences in a few
prognostic factors between the two groups. The two
peaks, however, have different ER-related heights with
the intersection of the two curves at three years, a result
that is nearly superimposable to what was obtained for
patients undergoing mastectomy [1].
An additional result supporting the lack of relevance
of the local treatment on the metastatic process is pro-
vided by the analysis of DM dynamics by site (Figure 4)
that yields results substantially identical to what was
obtained for patients undergoing mastectomy [4].
Local Recurrence Dynamics
Although the analysis of the IBTR dynamics yields a
bimodal hazard rate pattern for both ERP and ERN
tumours, there is a profound difference in the peak tim-
ing between the two ER categories (Figure 5). This find-
ing is a remarkable exception to the recurrence risk
rhythm, thoroughly congruent with a common metasta-
sis development pathway, till now observed in all ana-
lyzed subsets (by tumour size, nodal status, menopausal
s t a t u s ,E Rc o n t e n t ,r e c u r r e nce site) of patients under-
going radical and conservative surgery with or without
adjuvant chemotherapy [1,4,16]. This timing signal dif-
ference may be a clue to different biological mechanisms
responsible for the single complex clinical event that
conventionally is ascribed to the outgrowth of residual
foci of malignant cells.
At least three mechanisms could be involved in IBTR
origin. A) Over 60% of all primary breast cancer speci-
mens contain additional foci of in-situ or micro-invasive
disease most of which are outside the index quadrant
[17,18], representing latent disease biologically similar to
a new primary. B) The tumour bed is fertile soil with
Figure 6 Hazard rate estimates for mortality in 1615 ERP
tumours and 427 ERN tumours from patients undergoing
conservative surgery (quadrantectomy or tumourectomy) plus
RT. The mortality risk patterns reveal differences between ERP and
ERN tumours in the clinical course of the disease during the critical
period spanning from clinical recurrence to death. Vertical lines
represent point-wise confidence interval for the model estimated
hazards, according to standard asymptotic theory.
Figure 5 Hazard rate estimates for IBTR in 1615 ERP tumours
and in 427 ERN tumours from patients undergoing
conservative surgery (quadrantectomy or tumourectomy) plus
RT. The dynamics of recurrence within the same breast irradiated
following tumourectomy or quadrantectomy is quite distinct and
different depending upon whether the resected tumor does or
does not bear sex hormone receptors. Vertical lines represent point-
wise confidence interval for the model estimated hazards, according
to standard asymptotic theory.
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with the IBTR occurring very much like the natural his-
tory of loco-regional recurrence after mastectomy (1).
C) Microscopic foci of residual disease may remain in
the tumour bed following surgery whereby the cytokine
soup in the local environment might kick start out-
growth cancer resulting in an early peak of IBTR. The
second and third mechanism might explain a selective
advantage for ERP cancer cells to re-grow or reseed in
this zone with a different dynamic to that of the ERN
cancer cells. Amongst other unique local features the
a d i p o s et i s s u ei sr i c hi nt h ee n z y m ea r o m a t a s et h a ti s
responsible for the peripheral conversion of circulating
androgens from the adrenal gland into oestradiol [19].
For IBTR dynamics, however, no timing effect is
expected by the first mechanism, while the two others
would theoretically shift peaks of ERP tumours in an
opposite direction in comparison with findings.
IBTR may also be produced by tumour cells lodged
within the breast to which adjuvant RT is administered.
RT causes both a conventional short-term tumouricidal
effect and the so called “tumour bed effect”,i nw h i c h
the radiation-induced vascular damage of the surround-
ing tissue more indirectly impairs tumour growth [20].
W ec a n n o t ,h o w e v e r ,r u l eo u tt h a tt h ed i f f e r e n tr e c u r -
rence peak timing is related to a differential effect of RT
on ERP and ERN tumour cells. This hypothesis is, how-
ever, weakened by the fact that in experimental models
ERN tumour cells display higher radiosensitivity than
ERP tumour cells [21], thus suggesting a possible retard-
ing effect contrary to the observed one.
Summarizing, different mechanisms could account for
IBTR timing namely: a mechanism identical to a new pri-
mary, a mechanism equivalent to metastatic re-seeding, a
mechanism related to the outgrowth of residual disease
(unique for each hormone receptor phenotype) and
finally the tumour bed effect. None of them seems to
yield a persuasive explanation. Therefore, we favour a
more general hypothesis, namely that the ERP status
per se is related to delayed IBTR appearance.
To colonize a new organ, disseminated tumour cells
must have the capacity to effectively interact with the
new microenvironment [22], both during a phase of
tumour dormancy and while active growth is going on
[16]. Different organ microenvironments may impose
distinct requirements for complete clinically relevant
colonization, thus resulting in a selective metastasis dis-
tribution [23]. In spite of these constraints, implying
heterogeneity of the seeded organ related conditions,
the hazard rate for recurrence in different sites display a
remarkably uniform pattern [1,4,16] (that is confirmed
in the present analysis on DM), strongly suggesting
similarity of tumour-microenvironment dynamic inter-
actions. The uniqueness of IBTR hazard rate pattern,
therefore, may be ascribed to the unique traits of the
tumour-microenvironment relationship within the organ
of tumour origin that apparently imposes more restric-
tive conditions to ERP tumour cells.
This picture is not unreasonable. Besides reports reveal-
ing the role of activated stroma on promoting tumour
growth [24-26], several lines of evidence using both in
vitro and in vivo model systems provide support for a sup-
pressive role of certain types of stroma. Breast carcinoma
cells exhibited a reduction in proliferation when cultured
in presence of normal breast mesenchymal cells [27].
Differentiation of transformed cells was obtained in vitro
in colon adenocarcinoma cell lines co-cultured with
embryonic mesenchyme [28]. A suppressive effect of nor-
mal fibroblasts was observed with ras-infected epithelial
cells [29] and with prostatic adenocarcinoma [30]. Normal
fibroblasts inhibited tumorigenic outgrowth of normal
breast epithelium in contrast to tumour fibroblasts [31].
Embryonal carcinoma cells were capable of full differentia-
tion and co-operated to the development of normal mice
upon injection into developing blastocysts [32,33]. Of
note, in a three-dimensional model of human breast stro-
mal-epithelial cell interaction, it was observed that normal
breast fibroblasts (obtained by normal reduction mammo-
plasty), but not fibroblasts from other sites could inhibit
or retard morphological transformation of normal and
pre-neoplastic epithelial cell lines [34]. Moreover, and
most important, normal fibroblasts had the ability to sup-
press oestrogen-induced growth of ERP pre-neoplastic
human breast epithelial cells. It is conceivable, therefore,
that the microenvironment within the residual breast tis-
sue may play a dominant regulatory role upon ERP breast
tumour cells enforcing more stringent constraints upon
growth within the operated breast than other tissues, thus
prolonging the latency to IBTR. By contrast, the breast tis-
sue conditions are apparently less constraining to ERN
cells, as IBTR dynamics is similar to the corresponding
recurrence dynamics among other tissues.
Mortality dynamics
The hazard rate curves for mortality reveal differences
between ERP and ERN tumours in the clinical course of
the disease during the critical span from clinical recur-
rence to death. As suggested for a similar delay observed
in patients undergoing mastectomy [1], both the different
frequency of recurrence in sites bearing dissimilar prog-
nosis (viscera vs bone vs soft tissue) [5,6] and differential
responsiveness to the post-recurrence administered
endocrine therapy [7,8] may account for a better post
recurrence prognosis for patients with ERP tumours.
Potential selection bias
It should be acknowledged that, for analyses like the pre-
sent one, there may be potential selection bias in the data.
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practice or systemic therapy, since the patients were
enrolled during a time span of about a decade. It is to be
noticed, however, that surgery, RT and systemic treatments
were performed according to constant guide-lines by the
same therapy units throughout the accrual of all examined
patients. Moreover, as detailed in the section “Patients and
methods”, the eligibility criteria of all examined series were
virtually identical. In our opinion, therefore, the potential
selection bias related to merging consecutive trials, which
could account for differences in clinical outcome, particu-
larly in local recurrence, is quite small.
Conclusions
I ft h er e s u l t so ft h ep r e s e n ts t u d ya r et a k e nt o g e t h e r
with the results of similar analyses on patients under-
going mastectomy [1,4,16], it may be concluded that the
DM dynamics is essentially equivalent for all tumours
and is unaffected by different primary tumour removal
modalities (mastectomy or quadrantectomy with or
without RT or tumourectomy with RT), in agreement
with the paradigm explicitly proposed by B. Fisher [35].
Local breast cancer recurrence dynamics are similar to
DM dynamics for both ERP and ERN tumours following
mastectomy while following conservative surgery plus
RT such a similarity is restricted to ERN tumours only.
Therefore, delays observed in the IBTR risk peaks for
ERP tumours following conservative surgery and post-
operative RT are a remarkable exception to the other-
wise common recurrence risk rhythm. This clinical
behaviour is likely to reveal a ER related relationship
between tumour cells and the breast tissue, which may
play a dominant regulatory role upon ERP breast
tumour cells with more stringent constraints than upon
ERN cells, for which the time to overt recurrence is
similar to the corresponding time of the other tissues.
All observed regular patterns in the clinical course of
ad i s e a s et h a tc o n v e r s e l ys h o w sah i g hd e g r e eo fh e t -
erogeneity modulated by host vs tumour interactions
should guide translating into clinical behaviours find-
ings from investigations on prognostic factors (e.g. stu-
dies on tumour gene expression profiles). More in
general, since life is by its very nature, a terminal con-
dition, we believe and our data support that more
careful attention should be paid to the temporal pat-
terns of cancer recurrence and death over the span fol-
lowing diagnosis and therapeutic intervention. Being or
becoming a member of a subgroup whose death is
more likely to occur very early or much later is impor-
tant for the discovery and testing of therapies designed
to delay these events, as well as, for planning one’sl i f e ,
in general. Timing is, after all, everything in all such
human events.
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